Author(s): Borrie MJ; Phillips NA; Best S; Anastasiou-Ventura P; Aydogan T; Beaudoin C; Beuk J; Celotto I; Cole L; Das S; Fogarty J; Fouquet C; Gnassi L; Henri-Bellemare C; Pilon R; Sands J; Stirbu A; Truemner J; Chan S; Tucker A; Gajraj J; Bhangu ...

Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) used wide inclusion criteria recruiting participants across the spectrum from normal cognition to cognitive impairment to all types of clinical dementia, including mixed dementia. 1173 participants comprising ...

Article GUID: 41435411

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139